Share-Based Payments (Tables)

3 Months Ended

Jul. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of allocation of share based compensation expense

Stock-based compensation expense was recognized as follows (table in thousands):

	Three Months Ended July 31,
	2023		2022
General and administrative	$	184	$	123
Sales and marketing	66		48
Research and development	11		3
Cost of oncology services	162		32
Total stock-based compensation expense	$	423	$	206

Summary of valuation assumptions for stock options

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2023 and 2022 were as follows:

	Three Months Ended July 31,
	2023	2022
Expected term in years	6	6
Risk-free interest rates	3.95%	2.87%
Volatility	62.83%	62.58%
Dividend yield	—%	—%

Summary of stock option activity

The Company’s stock options activity for the three months ended July 31, 2023 was as follows:

	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2023	1,739,336	36,331	1,775,667	$	4.80	4.6	$	2,683,000
Granted	68,600	—	68,600	6.11		9.9
Exercised	(40,897)	—	(40,897)	2.90
Forfeited	(2,000)	—	(2,000)	4.18
Canceled	(34,618)	—	(34,618)	3.98
Expired	—	—	—
Outstanding, July 31, 2023	1,730,421	36,331	1,766,752	4.91		4.6	$	4,254,000
Vested and expected to vest as of July 31, 2023	1,730,421	36,331	1,766,752	4.91		4.6	$	4,254,000
Exercisable as of July 31, 2023	1,491,784	1,875	1,493,659	4.62		4.0	$	4,103,000